Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

Summary

The aim of the study is to examine whether determining treatment strategies based upon Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome in patients with psychosis. The investigators predict that prospectively testing CYP2D6 genotype and using this information to treat psychotic patients with risperidone will improve clinical outcomes. Specifically, CYP2D6 poor metabolizers who are treated with low dose and slow titration of risperidone will do better than those who are treated with usual dose and titration approach in terms of rates of side effects and clinical improvement.

Timeline

Start

2009-09-23

Primary completion

2018-07-31

Completion

2018-07-31

Drugs

Indications